ResearcherErasmus MCActive in the last 2 years
Henk M.W. Verheul
Matched on ORCID iD 0000-0001-5981-922X; OpenAlex author ID A5088673015. Sources: ClinicalTrials.gov.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 trial · 2024: none · 2025: 1 paper
Papers 3
- Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Co-author DOI 10.1016/j.pan.2025.03.011↗
- Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Co-author DOI 10.1038/srep44686↗
- Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced … Last author DOI 10.1158/1078-0432.ccr-14-3364↗
Trials 1
- Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI Principal investigator NCT04954599↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nuria Kotecki · 1 shared trial, 2023 · strength 0.36
- Sylvie Rottey · 1 shared trial, 2023 · strength 0.36
- Irene Brana · 1 shared trial, 2023 · strength 0.36
- Loes Jansen · 1 shared trial, 2023 · strength 0.36
- Johanna W. Wilmink · 2 shared papers, 2015–2025 · strength 0.28
- Paper Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. DOI 10.1016/j.pan.2025.03.011↗
- Paper Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-B… DOI 10.1158/1078-0432.ccr-14-3364↗
- Annette A. van Zweeden · 2 shared papers, 2015–2025 · strength 0.28
- Paper Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. DOI 10.1016/j.pan.2025.03.011↗
- Paper Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-B… DOI 10.1158/1078-0432.ccr-14-3364↗
- Jeanin Elise van Hooft · 1 shared paper, 2025 · strength 0.24
- Esther N. Pijnappel · 1 shared paper, 2025 · strength 0.24
- Hanneke W.M. van Laarhoven · 1 shared paper, 2025 · strength 0.24
- Lydia G. van der Geest · 1 shared paper, 2025 · strength 0.24
- Judith de Vos‐Geelen · 1 shared paper, 2025 · strength 0.24
- Martijn W.J. Stommel · 1 shared paper, 2025 · strength 0.24
- Elisa Giovannetti · 2 shared papers, 2015–2017 · strength 0.12
- Paper Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platfo… DOI 10.1038/srep44686↗
- Paper Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-B… DOI 10.1158/1078-0432.ccr-14-3364↗
- Maria N. Rovithi · 1 shared paper, 2017 · strength 0.07
- Amir Avan · 1 shared paper, 2017 · strength 0.07
- Niccola Funel · 1 shared paper, 2017 · strength 0.07
- Valentina E. Gómez‐Mellado · 1 shared paper, 2017 · strength 0.07
- Martijn Ruben Meijerink · 1 shared paper, 2015 · strength 0.05
- Geertjan van Tienhoven · 1 shared paper, 2015 · strength 0.05
- Anna M E Bruynzeel · 1 shared paper, 2015 · strength 0.05
- Geert Kazemier M · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.